PASADENA, Calif.--(BUSINESS WIRE)--Sanguine Corporation (OTC Bulletin Board: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells and numerous other areas requiring oxygen profusion, in collaboration with its FDA testing contractors and development team, recently added additional management contractors to aid in moving the Company through the 510(k) device application process. The new contractors are intended to aid in managing the 510(k) approval and capitalization path.
